Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Veerle Surmont"'
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-5 (2021)
Abstract Background The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of next-generation sequencing, un
Externí odkaz:
https://doaj.org/article/52eb1e13ea884b6cbb63be2a7bb85b52
Autor:
Quincy Chu, MD, Natasha B. Leighl, MD, Veerle Surmont, MD, Carla van Herpen, MD, PhD, Anne Sibille, MD, Ben Markman, MD, Stephen Clarke, MD, Rosalyn A. Juergens, MD, PhD, Mirelis Acosta Rivera, MD, Vladimir Andelkovic, MD, Charles M. Rudin, MD, PhD, Stephanie Snow, MD, Dong-Wan Kim, MD, Michael Sanatani, MD, Hongxia Lin, PhD, Kinjal Sanghavi, PhD, Sarah Tannenbaum-Dvir, MD, Paul Basciano, MD, Deanne Lathers, PhD, Katarzyna Urbanska, PhD, Georgia Kollia, PhD, Chunsheng He, PhD, Andrew DiPiero, BS, Yu Liu, MD, PhD, Neal Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100400- (2022)
Introduction: Fucosyl-GM1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-986012 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal antibody that binds to fucosyl-
Externí odkaz:
https://doaj.org/article/f5bd2944b1a6435ab4a355125a671725
Autor:
Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Veerle Surmont, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, Dirk Van Gestel, Vincent Renard, Piet Dirix, Pieter Mestdagh, Piet Ost
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical dat
Externí odkaz:
https://doaj.org/article/e63e874a32664919a1b011b24efc5c07
Autor:
Lennart Raman, Malaïka Van der Linden, Kim Van der Eecken, Karim Vermaelen, Ingel Demedts, Veerle Surmont, Ulrike Himpe, Franceska Dedeurwaerdere, Liesbeth Ferdinande, Yolande Lievens, Kathleen Claes, Björn Menten, Jo Van Dorpe
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-12 (2020)
Abstract Background Accurate lung cancer classification is crucial to guide therapeutic decisions. However, histological subtyping by pathologists requires tumor tissue—a necessity that is often intrinsically associated with procedural difficulties
Externí odkaz:
https://doaj.org/article/63038e3790a042e2aee27203f717ee9e
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionThis report investigates the impact of systemic treatments (chemotherapy or immunotherapy) with(out) loco-regional radiotherapy, on HRQoL, toxicity and neurocognitive functioning (NCF) in locally advanced and metastatic non-small cell lun
Externí odkaz:
https://doaj.org/article/e14546977ada4406b4d8730ba64f8153
Autor:
Sami Antoun, Hugues Morel, Pierre‐Jean Souquet, Veerle Surmont, David Planchard, Franck Bonnetain, Pascal Foucher, Thomas Egenod, Ivan Krakowski, Hélène Gaudin, Didier Debieuvre
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 4, Pp 782-793 (2019)
Abstract Background An international consensus proposed in 2011 a definition and classification system for cachexia (CAX), mainly based on weight loss, sarcopenia [skeletal muscle mass (SMM) loss], inflammation, and anorexia. The aim of this study wa
Externí odkaz:
https://doaj.org/article/7ebd8439cd9c42dd876e2a758f56bfab
Autor:
Malaïka Van der Linden, Bram Van Gaever, Lennart Raman, Karim Vermaelen, Ingel Demedts, Veerle Surmont, Ulrike Himpe, Yolande Lievens, Liesbeth Ferdinande, Franceska Dedeurwaerdere, Joni Van der Meulen, Kathleen Claes, Björn Menten, Jo Van Dorpe
Publikováno v:
Cancers, Vol 14, Iss 8, p 2031 (2022)
Diagnosis of lung cancer requires histological examination of a tissue sample, which in turn requires an invasive procedure that cannot always be obtained. Circulating tumor DNA can be reliably detected in blood samples of advanced-stage lung cancer
Externí odkaz:
https://doaj.org/article/ef26b07b88ff43e688590366b9e3a9e0
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-relate
Externí odkaz:
https://doaj.org/article/441f4b9328f94cf4a04e2e90fc0b48ca
Autor:
Lotte van der Weijst, David Azria, Patrick Berkovic, Pierre Boisselier, Erik Briers, Renée Bultijnck, Jenny Chang-Claude, Ananya Choudhury, Gilles Defraene, Sylvian Demontois, Rebecca M. Elliott, Dawn Ennis, Corinne Faivre-Finn, Marzia Franceschini, Tommaso Giandini, Alexandra Giraldo, Sara Gutiérrez-Enríquez, Carsten Herskind, Daniel S. Higginson, Sarah L. Kerns, Kerstie Johnson, Maarten Lambrecht, Philippe Lang, Mónica Ramos, Tiziana Rancati, Andreas Rimner, Barry S. Rosenstein, Dirk De Ruysscher, Ahmed Salem, Claudia Sangalli, Petra Seibold, Paloma Sosa Fajardo, Elena Sperk, Hilary Stobart, Holly Summersgill, Veerle Surmont, Paul Symonds, Begoña Taboada-Valladares, Christopher J. Talbot, Ana Vega, Liv Veldeman, Marlon R. Veldwijk, Tim Ward, Adam Webb, Catharine M.L. West, Yolande Lievens
Publikováno v:
Radiotherapy and Oncology, 176, 127-137. Elsevier Ireland Ltd
BACKGROUND AND PURPOSE: To investigate the association between clinician-scored toxicities and patient-reported health-related quality of life (HRQoL), in early-stage (ES-) and locally-advanced (LA-) non-small cell lung cancer (NSCLC) patients receiv
Publikováno v:
Technical Innovations & Patient Support in Radiation Oncology, Vol 21, Iss, Pp 36-40 (2022)
TECHNICAL INNOVATIONS & PATIENT SUPPORT IN RADIATION ONCOLOGY
TECHNICAL INNOVATIONS & PATIENT SUPPORT IN RADIATION ONCOLOGY
This observational cohort study investigates neurocognitive functioning (NCF) and its associations with overall survival (OS), disease-free survival (DFS) and patient-reported psychological toxicities in locally-advanced and metastatic non-small cell